Program

M. Pinzani: Pharmacology treatment issues in peri-transplant patients

Massimo Pinzani, M.D., Ph.D., Professor of Medicine, Department of Internal Medicine, Director Liver Laboratory (Unit 6), Center for Research, High Education and Transfer DENOThe, University of Florence, Florence, Italy Prof. Pinzani is a physician scientist with full training in clinical and ...
Read more

K. Schwarz: Treatment of HBV and HCV in the pediatric patient population

Dr. Schwarz received her medical training at Washington University School of Medicine and trained in Pediatrics and Pediatric Gastroenterology at St. Louis Children’s Hospital, Washington University School of Medicine. She was an Instructor of Pediatric Gastroenterology there and then moved to St. Louis University School of Medicine where she was Chief of the Division of Pediatric Gastroenterology and Nutrition. In 1987 she moved to Johns Hopkins ...
Read more

B. Poland - PK/PD modeling

Bill Poland, PhD is Vice President and Lead Scientist within Strategic Consulting Services at Pharsight Corporation. His group provides guidance in drug development decisions through drug-disease and trial modeling and simulation in major therapeutic areas. In HCV and HIV therapy, he and his group have used integrated adherence, pharmacokinetic, pharmacodynamic, and trial outcome models to support trial ...
Read more

K. Struble - HCV drug development

Dr. Kimberly Struble is currently a Medical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. She received a baccalaureate of Science in Pharmacy from the University of Connecticut and a Doctor of Pharmacy from the University of Arkansas for Medical Sciences. Dr Struble joined FDA in October 1993 and served in positions with Drug Information and the Division of Antiviral Products ...
Read more

4th International Workshop on Hepatitis C Resistance New Compounds &

4th International Workshop on Clinical Pharmacology of Hepatitis Therapy

B. Adiwijaya: PKPD modeling of the evolution of HCV to guide drug development

Dr. Bambang S. Adiwijaya, Ph. D., is a Senior Pharmacometrician of Vertex Pharmaceuticals, Inc., Cambridge, MA, where he focuses on developing computational models of HCV disease and treatments. His main interest involves the applications of advanced computational tools to guide drug development, in ...
Read more

D. Dubois: Pre-existing variants - an overview on deep sequencing technologies

Dwight DuBois, MD, is the President and Laboratory Director of Cenetron Diagnostics and Cenetron Central Laboratories, based in Austin, Texas, USA. Dr. DuBois received his MD degree from the University of Texas (San Antonio), and completed a residency in Internal Medicine at Case-Western Reserve University, followed by a NIH-sponsored fellowship in Infectious Diseases at the University of Washington. ...
Read more

S. Ray: Overview of genetic diversity of Hepatitis viruses: implications for therapy

Dr. Stuart C. Ray, M.D. Associate Professor of Medicine, Johns Hopkins University (JHU) School of Medicine, Baltimore, MD USA. Dr. Ray's laboratory research is focused on understanding the genomic sequence variation hepatitis viruses, particularly hepatitis C virus, in the context of the host immune response and disease pathogenesis. Dr. Ray graduated from Vanderbilt University School of Medicine ...
Read more

D. Standring -

David N. Standring, Ph.D., is Executive Vice President, Biology at Idenix Pharmaceuticals and has had roles of increasing responsibility since joining Idenix as Executive Director, Research in September 2000. Prior to joining Idenix, Dr. Standring led HBV and HCV programs at Schering Plough from 1998 to 2000 and at Bristol-Myers Squibb from 1994 to 1998. From 1984 to 1994, Dr. Standring was on the faculty of the University of California at San Francisco where his laboratory elucidated ...
Read more

Home